Dr Priscilla Nyambayo is a distinguished leader, astute and forward-thinking Clinical Pharmacologist with 26 years of experience and a history of achievements in the regulation of clinical trials, pharmacovigilance, and post-marketing surveillance. She is Head Pharmacovigilance and Clinical Trials Division, Medicines Control Authority of Zimbabwe. As a result, the Medicines Control Authority of Zimbabwe (MCAZ) obtained, WHO Global Bench Marking Maturity level 3 on 27 August 2021 for Clinical Trials Regulation Oversight (CTO) and WHO Maturity level 3 for Vigilance (VL) on 18 May 2023 and overall ML3 for all regulatory functions in May 2024. She successfully qualified as Doctor of Philosophy (PhD) at the University of Cape Town. The PhD in Public Health is titled “The use of m-Health to improve post-marketing surveillance of vaccines in Zimbabwe A case study of Zimbabwe Stimulated Telephone Assisted Rapid Safety Surveillance (Zm-STARSS) randomized controlled trial (RCT) assessing Adverse Events Following Immunisation (AEFIs)- Pharmacovigilance initiatives for COVID-19 vaccines in Zimbabwe. Dr Nyambayo a passionate advocate for patient safety regularly speaks at international conferences sharing her insights in vigilance, and clinical trials research regulations to promote accelerated research and access of safe, quality and effective medical products.